Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 20, 2010. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions.
- Share Purchase Price: £12.78 per share
- Transaction Date: January 14, 2010
- Dividend Re-investment Date: January 7, 2010
Material Changes
The filing reports an increase in the ordinary share interests of three individuals through the GlaxoSmithKline Annual Investment Plan. No financial performance changes or comparative period data are included in this report.
- Dr M M Slaoui: Acquired 279 shares
- Mr M Dunoyer: Acquired 136 shares
- Dr D Pulman: Acquired 208 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share purchases.
Key Facts for Investor Verification
- Verify the total number of shares held by Dr M M Slaoui, Mr M Dunoyer, and Dr D Pulman following these transactions.
- Confirm the dividend amount paid on January 7, 2010, that was re-invested to purchase these shares.
- Check subsequent filings to determine if these individuals have made further transactions in the company's ordinary shares.